Market News AIOpen the app

NGEN stock news · NervGen Pharma

Stories about NervGen Pharma (NGEN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for NGEN

Follow NervGen Pharma (NGEN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NGEN
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 9:09 AM ET · Trial

    NervGen Pharma shared its Q3 2026 results and said its NVG-291 drug got FDA Breakthrough Therapy status.

    Good for NGEN

    NervGen's Phase 3 study is advancing, with results expected in the first half of 2028. Cash should last until then, and the FDA designation makes this a positive update.